# Virtu Pharmako

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/virtu-pharmako

- Industry: Biotechnology
- Headquarters: Jiaxing, China
- Website: www.virtupharmako.com
- Latest round: Series A (Oct 30, 2024)
- Investors on record: 1

## About

Founded in 2021, and based in Jiaxing, China, Virtu Pharmako is an innovative biopharmaceutical developer that specializes in biopharmaceuticals, primarily GLP-1 analogs and insulin products. The company has cooperated with Huazhong Agricultural University and has a branch office in America. In October 2024, it closed a series A funding from new investor Yongkan Investment. The round is part of larger CNY 250 million series A funding.

Virtu Pharmako specializes in the development and production of innovative biopharmaceutical products, primarily focusing on GLP-1 analogs, insulin products, and recombinant enzymes. These products are designed to address various medical conditions, including metabolic diseases and cancer treatment, and are marketed to healthcare providers and pharmaceutical companies in both domestic and international markets, particularly in North America and Europe.

The company generate revenue by selling biopharmaceutical products, including GLP-1 and insulin-based therapies, typically structured as wholesale agreements and supply contracts. Collaborations with academic institutions also enhance revenue generation through research initiatives.

The company will use the series A funding for product clinical research, production project construction, and daily operations. The company is focused on launching new products designed for chronic conditions, with specific plans to expand into North American and European markets by mid-2025, aiming to enhance its product offerings and market presence.

## Funding rounds

- Series A, Oct 30, 2024 — Yongkan Investment
- Series A, Oct 30, 2024 — Yongkan Investment

## Investors

- Yongkan Investment (https://capitalatlas.ai/funds/yongkan-investment) — Series A